glp 1 with kidney disease ICYMI: GLP-1 Agonists Show Promise in Slowing in Lupus Nephritis Repurposing Diabetes Therapies in CKD:

And vice versa, cognitive and behavioral tests might be influenced by motor performance or sensory disturbances [7, 8]

Skeletal muscle is: A major contributor to resting metabolic rate A key site for glucose metabolism Essential for strength, mobility and independence Losing muscle can lower the number of calories your body burns at rest

Subcutaneous injection protocols typically use 200 to 400 micrograms daily

Pancreatic Inflammation & Potential Pancreatic Damage While GLP-1 receptor agonists (e.g., Ozempic, Wegovy, Mounjaro) are widely used and carry established warnings for acute pancreatitis, extensive large-scale studies show the overall absolute risk remains very low, and long-term data indicates they do not increase the lifetime risk of pancreatic damage for most patients Pancreatitis is a known risk of GLP-1 drugs, but long-term consequences are still being studied